Surmount 1 Trial results - using terzepatide (Mounjaro, Zepbound) in people with pre-diabetes

Recently a study called Surmount 1 was published in the New England Journal of Medicine. The study looked at the effect of tirzepatide (Mounjaro, Zepbound) on obesity in people with pre-diabetes. Among the key findings of the Surmount 1 trial:

After 176 weeks, participants in the placebo group lost only 1.3% of their body weight.
Patients in the tirzepatide group lost an average of:

• 12.3% on the 5-mg dose

• 18.7% on the 10-mg dose

• 19.7% on the 15-mg dose

Even more impressively, only 1.3% of patients on tirzepatide developed diabetes while 13.3% of the placebo group did. Even after being off treatment or placebo for 17 weeks, only 2.4% of the participants who had been on tirzepatide developed diabetes while 13.7% of those on placebo did.

The bottom line is that obesity is a chronic disease that leads to other chronic diseases such as diabetes. Weight loss and diabetes medications such as tirzepatide help you to lose weight while lowering your risk of developing diabetes.